Table 6. Final health outcomes (2)

| Study, year | Study group | Followup | DLQI\*  mean(SD) | HAQ-DI  mean(SD) | EQ-5D†  mean(SD) | SF-36  mean(SD) | Other reported outcomes |
| --- | --- | --- | --- | --- | --- | --- | --- |
| CT5 | Etanercept | 2w  4w  8w  12w  18w  24w | ---  ---  ---  ---  ---  --- | ---  ---  ---  ---  ---  --- | ---  ---  ---  ---  ---  --- | ---  ---  ---  ---  ---  --- | ---  ---  ---  ---  ---  --- |
|  | Acitretin | 2w  4w  8w  12w  18w  24w | ---  ---  ---  ---  ---  --- | ---  ---  ---  ---  ---  --- | ---  ---  ---  ---  ---  --- | ---  ---  ---  ---  ---  --- | ---  ---  ---  ---  ---  --- |
| Gelfand, 2012 | MTX | NR | 3(1-5)‡ | --- | --- | --- | --- |
|  | Adalimumab | NR | 2(0-5)‡ | --- | --- | --- | --- |
|  | Etanercept | NR | 2(1-5)‡ | --- | --- | --- | --- |
|  | Ustekinumab | NR | 3(1-6)‡ | --- | --- | --- | --- |
|  | NB-UVB | NR | 3(1-7)‡ |  |  |  |  |
| Barker, 2011 | Infliximab | 10w  16w  26w§ | -11.4(NR)  -11.6(NR)  -11.3(NR) | ---  ---  --- | 0.86(NR)  0.86(NR)  0.86(NR) | 5.15(NR)||, 7.94(NR)¶  5.53(NR)||  --- | ---  ---  --- |
|  | MTX | 10w  16w  26w§ | -7.9(NR)  -8.95(NR)  -9.14(NR) | ---  ---  --- | 0.81(NR)  0.84(NR)  0.81(NR) | 3.00(NR)||, 5.63(NR)¶  3.76(NR)||  --- | ---  ---  --- |
|  | Infliximab transitioned to MTX | --- | --- | --- | --- | --- | --- |
|  | MTX transitioned to infliximab | --- | --- | --- | --- | --- | --- |
| Inzinger, 2011 | Adalimumab | --- | --- | --- | --- | --- | --- |
|  | Alefacept | --- | --- | --- | --- | --- | --- |
|  | Etanercept | --- | --- | --- | --- | --- | --- |
|  | Infliximab | --- | --- | --- | --- | --- | --- |
|  | Ustekinumab | --- | --- | --- | --- | --- | --- |
|  | PUVA | --- | --- | --- | --- | --- | --- |
| Strober, 2011 | MTX transitioned to adalimumab | 4w  16w | -4.8(5.89)  -7.0(7.45) | ---  --- | ---  --- | ---  --- | ---  0.7(3.4)\*\*  -4.0(28.1)††  -5.5(30.3)‡‡  -13.3(33.1)§§ |
|  | NB-UVB transitioned to adalimumab | 4w  16w | -5.2(5.45)  -6.5(6.44) | ---  --- | ---  --- | ---  --- | ---  1.3(4.8)\*\*  -6.4(19.8)††  -8.0(19.4)‡‡  -12.2(25.6)§§ |
| Garavaglia, 2010 | CyA transitioned to etanercept | --- | --- | --- | --- | --- | --- |
| Caproni, 2009 | Etanercept | --- | --- | --- | --- | --- | --- |
|  | Acitretin | --- | --- | --- | --- | --- | --- |
| Mazzotta, 2009 | Nonbiologics or phototherapy transitioned to etanercept|||| | --- | --- | --- | --- | --- | --- |
| Gisondi, 2008a | Etanercept | --- | --- | --- | --- | --- | --- |
|  | Acitretin | --- | --- | --- | --- | --- | --- |
| Gisondi, 2008b | Etanercept | --- | --- | --- | --- | --- | --- |
|  | Infliximab | --- | --- | --- | --- | --- | --- |
|  | MTX | --- | --- | --- | --- | --- | --- |
| Saurat, 2008 | Adalimumab | 12w  16w  70d¶¶ | -9.1(-10.4, -7.8)\*\*\*  -9.1(-10.4, -7.8)\*\*\*  --- | ---  ---  --- | IS: 0.2(0.1, 0.2)\*\*\*  VAS: 20.4(15.3, 25.4)\*\*\*  IS: 0.2(0.2, 0.3)\*\*\*  VAS: 21.4(16.6, 26.3)\*\*\*  --- | ---  ---  --- | ---  ---  --- |
|  | MTX | 12w  16w  70d¶¶ | -4.9(-5.9, -3.8)\*\*\*  -5.7(-6.8, -4.5)\*\*\*  --- | ---  ---  --- | IS: 0.1(0.1, 0.2)\*\*\*  VAS: 10.2(5.3, 15.2)\*\*\*  IS: 0.1(0.1, 0.2)\*\*\*  VAS: 11.5(6.5, 16.5)\*\*\*  --- | ---  ---  --- | ---  ---  --- |
|  | MTX transitioned to adalimumab | --- | --- | --- | --- | --- | --- |
| Magliocco, 2007 | CyA transitioned to alefacept | 0w  13w  25w  37w  48w | 3.18(NR)†††  1.09(NR)†††  4.88(NR)†††  3.14(NR)†††  3.83(NR)††† | ---  ---  ---  --- | ---  ---  ---  --- | ---  ---  ---  --- | ---  ---  ---  --- |
| Costanzo, 2005 | Nonbiologics transitioned to etanercept‡‡‡ | --- | --- | --- | --- | --- | --- |

Abbreviations:CyA=cyclosporine; d=day(s); DLQI=Dermatology Life Quality Index; EQ-5D=EuroQol-5D; HAQ-DI= Health Assessment Questionnaire Disability Index; IS=index score; MACE=major adverse cardiovascular event; MTX=methotrexate; n/N=number of patients per total population; NB-UVB=narrowband ultraviolet B; NR=not reported; PUVA=psoralen plus ultraviolet A; SD=standard deviation; SF-36=Short form-36; VAS=visual analogue scale; w=week(s); ---=not reported

\* Mean(SD) change from baseline, unless otherwise noted

† Mean(SD) composite score, unless otherwise noted

‡ Median (IQR) DLQI

§ Includes patients who switched treatments at week 16 as nonresponders

|| Mean(SD) change from baseline in Physical Component Score of SF-36

¶ Mean(SD) change from baseline in Mental Component Score of SF-36

\*\* Mean(SD) change from baseline in percent work time missed due to psoriasis

†† Mean(SD) change from baseline in percent overall work impairment due to psoriasis

‡‡ Mean(SD) change from baseline in percent impairment while working due to psoriasis

§§ Mean(SD) change from baseline in percent activity impairment due to psoriasis

|||| CyA, corticosteroids, fumaric acid esters, MTX, retinoids, PUVA

¶¶ 70 days after last treatment

\*\*\* Mean(95% confidence interval) change from baseline

††† Mean(SD) DLQI

‡‡‡ CyA, corticosteroids, MTX, retinoids